Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 18 2025
0mins
Source: PRnewswire
CAM2029 Efficacy: The Phase 2b POSITANO study demonstrated that CAM2029 significantly reduces liver and cyst volume in patients with symptomatic polycystic liver disease (PLD) compared to placebo, while also improving patient-reported symptoms.
Safety and Future Studies: CAM2029 was well tolerated with no new safety concerns, and Camurus plans to discuss a follow-up Phase 3 study with regulatory authorities based on these promising results.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
